Abstract
Bruton tyrosine kinase inhibitors (BTKi) have changed the treatment paradigm for mantle cell lymphoma (MCL). In this issue of Blood, Le Gouill et al(1......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
